You are here

ANTI-IDIOTYPE VACCINES AGAINST FLAVIVIRUSES

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13653
Amount: $49,978.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1990
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
12111 Parklawn Dr
Rockville, MD 20852
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Bennett M Kaufman
 (301) 770-3099
Business Contact
Phone: () -
Research Institution
N/A
Abstract

THE GOAL OF THIS RESEARCH IS THE DEVELOPMENT OF A MURINE MONOCLONAL ANTI-IDIOTYPE VACCINE THAT WILL ELICIT NEUTRALIZING ANTIBODIES AGAINST THE FLAVIVIRUS GROUP OF ARBOVIRUSES, IN PARTICULAR DENGUE TYPES 1-4. IN PHASE I, MICE WILL BE IMMUNIZED WITH A PREVIOUSLY CHARACTERIZED MURINE MONOCLONAL ANTIBODY (AB1) THAT RECOGNIZES A CROSS-PROTECTIVE GROUP-REACTIVE DETERMINANT ON THE ENVELOPE GLYCOPROTEIN OF FLAVIVIRUSES. THE SPLEENS OF AB1-IMMUNIZED MICE WILL BE USED AS A SOURCE OF CELLS TO PRODUCE HYBRIDOMAS SECRETING MONOCLONAL ANTIBODIES DIRECTED AGAINST THE HYPERVARIABLE REGION OF AB1 (INTERNAL IMAGE ANTI-IDIOTYPE ANTIBODIES, AB2 ). AB2 WILL BE CHARACTERIZED BY ELISAAND BY IMMUNOBLOTTING, AND FOR INHIBITORY ACTIVITY IN A PLAQUE REDUCTION NEUTRALIZATION ASSAY. AB2 WILL FURTHER BE USED TO IMMUNIZE MICE TO ELICIT ANTIBODIES REACTIVE WITH NATIVE FLAVIVIRUS E-GLYCOPROTEIN (AB3). THESE STUDIES WILL LAY THE FOUNDATION FOR SUBSEQUENT ANTI-IDIOTYPE VACCINE PRECLINICAL AND CLINICAL SAFETY AND EFFICACY TRIALS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government